Aliphatic Propargylamines as Treatments for Neurodegenerative Diseases
During the past decade, apoptosis has been implicated increasingly as playing a role in a number of human neurodegenerative conditions. The acceptance of a role for apoptosis in human disease states has led to a marked increase in attempts to develop anti-apoptotic agents as potential therapeutics. We have developed a number of novel aliphatic compounds, several of which have been tested in a number of in vitro and in vivo model systems (Berry, 1999). Here we focus on data obtained from in vivo models of two neurodegenerative conditions, stroke and Parkinson’s disease.
KeywordsTyrosine Catecholamine Monoamine MPTP Alan
Unable to display preview. Download preview PDF.
- Berry, M. D. and Boulton, A. A., 2001, Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases, Neurotoxicol. Teratol. (in press).Google Scholar